EL
ELMD.US Electromed Inc
- Market cap
- USD 199M
- P/E
- 17.6x
- P/B
- 3.89x
- ROE
- 21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is ELMD.US undervalued?
Graham numberELMD.US trades 74.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Electromed Inc fundamental analysis
No fundamental analysis for Electromed Inc yet.
Electromed Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Electromed Inc
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, …
Full company profileElectromed Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Electromed Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.9M | 28.3M | 31.3M | 32.5M | 35.8M | 41.7M | 48.1M | 54.7M | 64.0M | 73.8M | 74.7M |
| Gross Profit | 20.6M | 21.8M | 23.8M | 25.2M | 27.3M | 31.4M | 36.5M | 41.7M | 50.0M | 57.9M | 59.7M |
| Operating Income | 3.57M | 2.71M | 2.83M | 5.12M | 3.14M | 2.97M | 4.01M | 6.58M | 9.87M | 13.9M | 14.0M |
| EBITDA | 4.32M | 3.50M | 3.75M | 5.86M | 3.78M | 3.63M | 4.70M | 7.88M | 11.5M | 15.0M | 14.5M |
| Net Income | 2.23M | 1.83M | 1.98M | 4.16M | 2.36M | 2.31M | 3.17M | 5.15M | 7.54M | 11.3M | 11.0M |
| EPS | 0.26 | 0.21 | 0.23 | 0.47 | 0.27 | 0.26 | 0.36 | 0.58 | 0.86 | 1.30 | 1.26 |
| Balance Sheet | |||||||||||
| Total Assets | 23.1M | 26.6M | 29.4M | 33.2M | 37.1M | 41.4M | 45.8M | 52.2M | 53.8M | 66.3M | 61.1M |
| Total Liabilities | 3.99M | 4.74M | 3.62M | 2.99M | 4.69M | 7.19M | 8.14M | 7.69M | 10.6M | 12.3M | 8.62M |
| Shareholders' Equity | 19.1M | 21.9M | 25.7M | 30.3M | 32.4M | 34.2M | 37.7M | 44.5M | 43.2M | 54.0M | 52.5M |
| Cash & Short-term Investments | 5.57M | 7.46M | 7.81M | 10.5M | 11.9M | 8.15M | 7.37M | 16.1M | 15.3M | 20.5M | 15.9M |
| Total Debt | 1.15M | 1.10M | 45.1K | 81.0K | 87.0K | 41.0K | 161K | 87.0K | 198K | 133K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.19M | 2.44M | 2.59M | 4.20M | 3.08M | -686K | 1.32M | 9.07M | 11.4M | 9.67M | 1.49M |
| Capital Expenditure | 687K | 572K | 1.39M | 977K | 448K | 1.53M | 1.72M | 395K | 306K | 1.25M | 660K |
| Free Cash Flow | 504K | 1.87M | 1.20M | 3.22M | 2.63M | -2.21M | -401K | 8.67M | 11.1M | 8.41M | 832K |
| Ratios | |||||||||||
| ROE | 11.7% | 8.4% | 7.7% | 13.8% | 7.3% | 6.7% | 8.4% | 11.6% | 17.4% | 20.9% | 21.0% |
| ROA | 9.7% | 6.9% | 6.7% | 12.5% | 6.4% | 5.6% | 6.9% | 9.9% | 14.0% | 17.1% | 18.1% |
| Net Profit Margin | 8.6% | 6.5% | 6.3% | 12.8% | 6.6% | 5.5% | 6.6% | 9.4% | 11.8% | 15.3% | 14.8% |
| Debt to Equity | 0.06x | 0.05x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Electromed Inc dividends
Electromed Inc has not paid dividends in the last 9 fiscal years.
Who owns Electromed Inc
- Insiders 17.45%
- Institutions 62.75%
- Public & others 19.80%
- Shares outstanding 8.17M
- Free float 6.76M
Electromed Inc company profile
- Company name
- Electromed Inc
- Ticker
- ELMD.US
- Exchange
- USA Stocks
- Listed since
- Aug 13, 2010
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 195
- Fiscal year end
- June
- Address
- 500 Sixth Avenue NW, New Prague, MN, United States, 56071
- Phone
- 952 758 9299
- Website
- smartvest.com
About Electromed Inc
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Electromed Inc management
2- Mr. James L. CunniffPresident, CEO & Director · born 1966
- Mr. Bradley M. NagelCFO, Treasurer & Secretary · born 1982